Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.
Jessica Zucman-Rossi, Emmanuelle Jeannot, Jeanne Tran Van Nhieu...
https://pubmed.ncbi.nlm.nih.gov/16496320/Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-12-26
25
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating a treatment for large inflammatory hepatocellular adenomas HCA, which are rare benign liver tumors mainly affecting young women using estrogen-based contraception. These tumors carry risks of bleeding and malignant transformation, often requiring liver surgery that can cause complications and cosmetic issues. This phase 2 open-label trial explores whether short-term use of the JAK12 inhibitor baricitinib can reduce tumor size and potentially avoid surgery. Participants will receive baricitinib, a drug that targets the JAKSTAT pathway activated in inflammatory HCA tumors. An ancillary study in 12 patients will use PET CT scans with 18 FDG to monitor tumor changes from baseline to 3 months. The main treatment period involves assessing tumor size changes at 3 and 6 months to determine response. Follow-up will continue up to 24 months to track surgery need, tumor growth, symptom occurrence, and adverse events. During the study, participants will undergo imaging assessments including PET CT and standard scans at scheduled intervals. Researchers will evaluate tumor size using RECIST 1.1 criteria, monitor for bleeding or malignant transformation, and record any side effects from baricitinib. Safety and long-term outcomes will be observed through visits at multiple time points up to two years after treatment starts.
CONDITIONS
A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
J
Jean Charles NAULT, PUPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive treatment with the JAK1 inhibitor baricitinib to reduce the size of large inflammatory hepatocellular adenomas.
Visits at baseline and during treatment assessments
Duration - Up to 18 months following treatment completion
Participants are monitored after treatment ends to assess tumor size, need for liver surgery, adverse events, and other outcomes up to 24 months.
Follow-up visits at Day 15, Month 1, Month 3, Month 6, Month 12, Month 18, and Month 24
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Jessica Zucman-Rossi, Emmanuelle Jeannot, Jeanne Tran Van Nhieu...
https://pubmed.ncbi.nlm.nih.gov/16496320/Gina A Montealegre Sanchez, Adam Reinhardt, Suzanne Ramsey...
https://pubmed.ncbi.nlm.nih.gov/29649002/Jean-Charles Nault, Valérie Paradis, Maxime Ronot...
https://pubmed.ncbi.nlm.nih.gov/35835851/Michelle Petri, Ian N Bruce, Thomas Dörner...
https://pubmed.ncbi.nlm.nih.gov/36848919/Steven R Ytterberg, Deepak L Bhatt, Ted R Mikuls...
https://pubmed.ncbi.nlm.nih.gov/35081280/Brett King, Manabu Ohyama, Ohsang Kwon...
https://pubmed.ncbi.nlm.nih.gov/35334197/Quentin Bayard, Stefano Caruso, Gabrielle Couchy...
https://pubmed.ncbi.nlm.nih.gov/31907296/Peter C Taylor, Edward C Keystone, Désirée van der Heijde...
https://pubmed.ncbi.nlm.nih.gov/28199814/Karine Poussin, Camilla Pilati, Gabrielle Couchy...
https://pubmed.ncbi.nlm.nih.gov/24501689/Safi Dokmak, Valérie Paradis, Valérie Vilgrain...
https://pubmed.ncbi.nlm.nih.gov/19664629/Assistance Publique - Hôpitaux de Paris
Lead Sponsor